Please assess the completion status of the following clinical trial:

Trial Title: Anti-anxiety Biotics for Breast Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Female breast cancer survivors or female relatives of a breast cancer survivor who:~1. are 50 years of age or older~2. have completed primary treatment~3. currently experience clinical anxiety symptoms determined by the 7 item Generalized Anxiety Disorder screener (GAD-7; eligibility requires a total score of 5 or higher on the 21 point scale)~4. agree not to change dietary supplements throughout the course of the study~5. are willing to comply with daily supplement regimen~6. are able to speak and read English.~Exclusion Criteria:~1. use of any of the following drugs within the last 4 weeks (unless indefinitely prescribed): systemic antibiotics, corticosteroids, immunosuppressive agents, or commercial probiotics~2. changes in treatment for anxiety symptoms (i.e. initiation of Cognitive Behavior Therapy (CBT) within the last four weeks~3. current use (within 12 weeks) of anxiolytic medications.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Synbiotic supplement group (Type: EXPERIMENTAL): Daily consumption of pills containing prebiotics and probiotics
- Placebo group (Type: PLACEBO_COMPARATOR): Daily consumption of pills containing maltodextrin

Based on this trial design, predict the completion outcome and termination type (if applicable).